Saxenda 3ml Liraglutide Injection Pen

Shopping Event
· Get more discount for bulk from 5 pcs

· Free shipping over 1500$

Saxenda (liraglutide 3ml injection pen)​​ is an FDA-approved prescription medication for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with weight-related conditions. Clinical trials demonstrate ​​56% of patients achieved ≥5% weight loss at 56 weeks​​ when combined with lifestyle changes, with an ​​average 8% body weight reduction​​. As a GLP-1 receptor agonist, it suppresses appetite by delaying gastric emptying by 31% and enhances satiety, while improving metabolic health markers like HbA1c (-0.6%) and systolic blood pressure (-2.8mmHg).

$108.00

Out of stock

Out of stock

Saxenda 3ml Liraglutide Injection Pen

Saxenda (liraglutide 6 mg/ml) is an FDA-approved prescription medication for chronic weight management. Clinical trials demonstrate that 56% of patients achieved ≥5% weight loss at 56 weeks when combined with lifestyle modifications. The 3ml pre-filled pen delivers 18mg liraglutide through easy-to-use multidose injections, working as a GLP-1 receptor agonist to regulate appetite and calorie intake.

Clinically Proven Efficacy

Average 8% body weight reduction observed in clinical studies over 12 months.

Appetite Regulation

Delays gastric emptying by 31% and increases satiety signals.

Metabolic Benefits

Improves HbA1c by 0.6% and systolic BP by 2.8mmHg in obese patients.

Mechanism of Action
  • GLP-1 receptor agonist: 97% amino acid sequence homology with human GLP-1
  • Reduces hunger through hypothalamic appetite center modulation
  • Slows gastric emptying rate by 20-30% post-meal
  • Enhances first-phase insulin response by up to 118%

Packaging Details

Active Ingredient: Liraglutide 6 mg/ml (18mg per 3ml pen)

Excipients: Sodium phosphate dibasic dihydrate, propylene glycol, phenol

Storage: Unopened: 2-8°C; In-use: ≤30°C for ≤30 days

Clinical Protocol
Administration

Subcutaneous injection in abdomen, thigh, or upper arm. Rotate sites.

Dose Escalation

Week 1-4: 0.6mg→1.2mg→1.8mg→2.4mg→3.0mg (weekly increments)

Monitoring

Assess weight loss at 16 weeks: discontinue if <4% baseline loss.

Important Safety Information

*Individual results may vary: Weight loss outcomes depend on metabolic factors and compliance.

Contraindicated in pregnancy, thyroid cancer history, or multiple endocrine neoplasia.

Requires prescription and medical supervision. Report adverse reactions to healthcare provider immediately.

0 reviews
0
0
0
0
0

There are no reviews yet.

Be the first to review “Saxenda 3ml Liraglutide Injection Pen”
Review now to get coupon!

Your email address will not be published. Required fields are marked *

Interested in Wholesale?

Contact Us Now

Be The First To Know About Wholesale, Exclusive Sales & More

Interested in Wholesale?

Contact Us Now

Be The First To Know About Wholesale, Exclusive Sales & More